1100 related articles for article (PubMed ID: 15934075)
1. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
2. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
Matsunawa M; Isozaki T; Odai T; Yajima N; Takeuchi HT; Negishi M; Ide H; Adachi M; Kasama T
Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
[TBL] [Abstract][Full Text] [Related]
3. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation.
Echigo T; Hasegawa M; Shimada Y; Takehara K; Sato S
J Allergy Clin Immunol; 2004 May; 113(5):940-8. PubMed ID: 15131578
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
5. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
6. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.
Ainiala H; Hietaharju A; Dastidar P; Loukkola J; Lehtimäki T; Peltola J; Korpela M; Heinonen T; Nikkari ST
Arthritis Rheum; 2004 Mar; 50(3):858-65. PubMed ID: 15022328
[TBL] [Abstract][Full Text] [Related]
7. Utility of interferon-α as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus.
Fragoso-Loyo H; Atisha-Fregoso Y; Núñez-Alvarez CA; Llorente L; Sánchez-Guerrero J
J Rheumatol; 2012 Mar; 39(3):504-9. PubMed ID: 22247358
[TBL] [Abstract][Full Text] [Related]
8. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
9. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus.
Yoshio T; Hirata D; Onda K; Nara H; Minota S
J Rheumatol; 2005 Jan; 32(1):34-9. PubMed ID: 15630721
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus.
Fragoso-Loyo H; Richaud-Patin Y; Orozco-Narváez A; Dávila-Maldonado L; Atisha-Fregoso Y; Llorente L; Sánchez-Guerrero J
Arthritis Rheum; 2007 Apr; 56(4):1242-50. PubMed ID: 17393453
[TBL] [Abstract][Full Text] [Related]
11. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
Kwieciński J; Kłak M; Trysberg E; Blennow K; Tarkowski A; Jin T
Arthritis Rheum; 2009 Jul; 60(7):2094-101. PubMed ID: 19565516
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
14. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.
Ruth JH; Volin MV; Haines GK; Woodruff DC; Katschke KJ; Woods JM; Park CC; Morel JC; Koch AE
Arthritis Rheum; 2001 Jul; 44(7):1568-81. PubMed ID: 11465708
[TBL] [Abstract][Full Text] [Related]
15. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.
Yu HH; Wang LC; Lee JH; Lee CC; Yang YH; Chiang BL
Rheumatology (Oxford); 2007 Sep; 46(9):1492-4. PubMed ID: 17673480
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus.
Guo L; Lu X; Wang Y; Bao C; Chen S
Exp Ther Med; 2017 Oct; 14(4):3153-3158. PubMed ID: 28912865
[TBL] [Abstract][Full Text] [Related]
17. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
Hasegawa M; Sato S; Echigo T; Hamaguchi Y; Yasui M; Takehara K
Ann Rheum Dis; 2005 Jan; 64(1):21-8. PubMed ID: 15608300
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
20. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
